NetworkNewsBreaks

WednesdayJun 28, 2017 9:32 am

NetworkNewsBreaks – SRAX (NASDAQ: SRAX) Announces New Tool Aimed at Extending the Reach of Facebook Posts

Internet advertising company SRAX (NASDAQ: SRAX) this morning announced the launch of a new SRAX Social tool for digital marketers and content owners designed to create and promote posts that extend beyond their Facebook page communities. This release is noteworthy as, according to industry reporting, organic reach for businesses on Facebook fell more than 50 percent last year. “Organic reach for brand content on Facebook has rapidly declined leading to strong demand to boost content on the social network and beyond,” Chris Miglino, CEO and chairman of SRAX, stated in the news release. “The ability to boost posts directly from…

Continue Reading

WednesdayJun 28, 2017 9:05 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Set to Launch New Skin Care Line in Q3 2017

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced that its wholly-owned foreign enterprise, CBD Biotechnology Co. Ltd., will officially launch its first line of non-industrial hemp infused skin care products, the ‘CBD Magic Hemp Series’, in the third calendar quarter of 2017. Four products will be featured in this line, including CBDBIO TECH Toner, CBDBIO TECH Rejuvenating Cream, CBDBIO TECH Perfecting Shield Primer and CBDBIO TECH Rejuvenating Spray. “Although China is one of the leading producers of industrial hemp, the benefits to the human body have not yet been widely recognized in mainland China,” Summer Yun, CEO of…

Continue Reading

TuesdayJun 27, 2017 12:23 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on June 27, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: MBRX 35.53% – News: Hosting a conference call on June 29 OWCP 22.71% – News: OWC subsidiary files U.S. patent application for active cannabinoid-based topical cream APDN 19.29% – News: Completes initial work under funded contract with Lily of the Desert; signs new licensing agreement with Himatsingka America SPEX 14.23% – News: Issues letter to shareholders ADMA 13.06% – News: Posts a corporate timeline and activities update IGXT 9.68% – News: Receives U.S. notice…

Continue Reading

TuesdayJun 27, 2017 12:07 pm

NetworkNewsBreaks – Xenon Pharmaceuticals, Inc. (NASDAQ: XENE) and Teva Pharmaceutical’s (NYSE: TEVA) Phase II Study of Topical TV-45070 in Patients with PHN Misses Primary Endpoint

Shares of Xenon Pharmaceuticals (NASDAQ: XENE) are down 18% after the company, along with Teva Pharmaceutical (NYSE: TEVA), released top-line results in a phase II study of topical TV-45070 in patients with post-herpetic neuralgia (PHN). TV-45070 did not meet the primary endpoint of a statistically significant change in pain from baseline to week four as assessed by the numeric rating scale. Additionally, the secondary endpoints were also not met. “While these results are disappointing for us from a scientific perspective and for patients needing new therapies to treat chronic neuropathic pain, Xenon remains focused on advancing its pipeline of neurology-related…

Continue Reading

TuesdayJun 27, 2017 12:04 pm

NetworkNewsBreaks – Rennova Health, Inc. (NASDAQ: RNVA) Shares Spike on New Partnership to Develop Direct to Consumer Molecular Testing for Psychiatric Disorders

Shares of Rennova Health (NASDAQ: RNVA) jumped 20% on news that the company’s subsidiary, Advanced Molecular Services Group, Inc. (AMS Group), has entered an agreement with Certainty Health, LLC to develop next generation smartphone tools. The tools will be developed to enable patients, families, and their health care teams to confidently assess the importance of a patients' genetic backgrounds in treatment decisions for various psychiatric diseases. Per the agreement, Rennova will market consumer-facing genetic tests developed by its AMS Group using the Certainty Health brand.  AMS Group anticipates general availability of the platform and online ordering of its molecular tests…

Continue Reading

TuesdayJun 27, 2017 9:27 am

NetworkNewsBreaks – ProBility Media Corp. (PBYA) Announces Acquisition of W Marketing, Inc.

Education technology company ProBility Media Corp. (OTCQB: PBYA) this morning announced that it has closed on its acquisition of W Marketing, Inc., a profitable, revenue-generating provider of National Electrical Codes (NECs) to the electrical and construction industries. “The closing of the acquisition of W Marketing highlights our commitment to aggressively building an international brand for education, training and compliance dedicated to the skilled trades,” Noah Davis, president and chief operating officer of ProBility, stated in the news release. “With the aggressive push from the current administration and the anticipated apprenticeship program, ProBility is positioned to take advantage of the projected…

Continue Reading

TuesdayJun 27, 2017 9:02 am

NetworkNewsBreaks – SinglePoint, Inc. (SING) Subsidiary Receives Major Purchase Order from Premier Biomedical (BIEI)

Specialized holding company SinglePoint, Inc. (OTC: SING) this morning announced that its recently-acquired DIGS Hydro subsidiary has received a major purchase order from Premier Biomedical (OTCQB: BIEI). DIGS Hydro has already received the initial payment for this order, with final payment due upon delivery. “This opportunity for both SinglePoint and DIGS Hydro is fantastic,” Greg Lambrecht, CEO of SinglePoint, stated in the news release. “We have been working very hard on making acquisitions and inside sales to boost revenues. To have this subsidiary execute on its business plan and generate major revenue for SinglePoint is exactly what we want to…

Continue Reading

MondayJun 26, 2017 3:44 pm

NetworkNewsBreaks – Kootenay Zinc Corp. (CSE: ZNK) (OTCQB: KTNNF) Announces Commencement of Drilling at Sully Property

Mineral exploration and development company Kootenay Zinc Corp. (CSE: ZNK) (OTCQB: KTNNF) today announced that its drilling contractor, FB Drilling Ltd., has mobilized to the E3 Target on its Sully Project and has commenced drilling. Ongoing exploration activities are focused on the discovery of sedimentary exhalative (SEDEX) deposits, which serve as the most important source of a number of ores, including zinc, lead and barite. As previously reported, the E3 target at the 1,375-hectacre Sully Project located in British Columbia, Canada, features a promising gravity anomaly. This anomaly will be tested for the first time as part of these drilling…

Continue Reading

MondayJun 26, 2017 1:19 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on June 26, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: SRNE 13.51% – News: Reports successful phase 1 / 2 trial of lead candidate, SP-102 for radicular pain MBRX 12.27% – News: Partners with Mayo Clinic physician to enable additional research on treatment for rare pediatric brain tumor ROKA 3.25% – News: Will co-host webcast entitled, “Food Safety Pixels to Pictures: How to Bring your Data to Life” XBIO 3.70% – News: Begins patient enrollment of phase 2 clinical study of XBIO-101 to treat…

Continue Reading

MondayJun 26, 2017 12:32 pm

NetworkNewsBreaks – Semnur Pharmaceuticals, Inc.’s (NASDAQ: SRNE) SP-102 Phase 1/2 Trial Meets Primary Endpoint, Preparing for Safety and Efficacy Studies; Shares Surge

Shares of Semnur Pharmaceuticals (NASDAQ: SRNE) are up 12.1% after the company posted positive data from is phase 1/2 pharmacokinetic bridging trial of its lead product, SP-102, for the treatment of lumbar radicular pain. The trial achieved its primary pharmacokinetic endpoint and demonstrated that a single epidural injection of SP-102 can provide a sustained analgesic effect for one month. Semnur said it will now move forward with the next stage of clinical trials. "We are very excited with the data from this first-in-human proof-of-principle study, which allows us to proceed with the planned Phase 3 safety and efficacy trials in…

Continue Reading